As an IC, you are seeing post-ACS/post-PCI patients whose atherosclerotic disease burden is exceptional and potentially amenable to PCSK9-mediated CV risk reduction. Where is your specific focus for using these agents in this population?

As an IC, you are seeing post-ACS/post-PCI patients whose atherosclerotic disease burden is exceptional and potentially amenable to PCSK9-mediated CV risk reduction. Where is your specific focus for using these agents in this population?

CLICK HERE FOR CME CREDIT

As an IC, you are seeing post-ACS/post-PCI patients whose atherosclerotic disease burden is exceptional and potentially amenable to PCSK9-mediayed CV risk reduction. Where is your specific focus for using these agents in this population?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

J. Wouter Jukema, MD, PhD, FESC, FACC MC

J. Wouter Jukema, MD, PhD, FESC, FACC MC

Professor of Cardiology Netherlands Heart Foundation Chairman, Leiden Vascular Medicine Leiden University Medical Center (LUMC) Leiden, Netherlands